Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus

Proteomics

Volumn 16, Issue 3, 2016, Pages 532-538

  Schubert, Klaus Oliver ^a,b   Föcking, Melanie ^a   Wynne, Kieran ^c   Cotter, David R ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Animal proteomic; Haloperidol; Hippocampus; MS; Schizophrenia

Indexed keywords

CLATHRIN; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOME; STRESS ACTIVATED PROTEIN KINASE; CYTOSKELETON PROTEIN; NERVE PROTEIN; NEUROLEPTIC AGENT; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; CYTOSKELETON; ENDOCYTOSIS; HIPPOCAMPUS; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TISSUE HOMOGENATE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MITOCHONDRION; MOLECULAR GENETICS; PROTEIN ANALYSIS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, LIQUID; CYTOSKELETAL PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE REGULATORY NETWORKS; HALOPERIDOL; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MOLECULAR SEQUENCE ANNOTATION; NERVE TISSUE PROTEINS; OXIDATIVE PHOSPHORYLATION; PROTEIN INTERACTION MAPPING; PROTEOME; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84958039078     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201500242     Document Type: Article

References (55)

1. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D. et al., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382, 951-962.
2. Gur, R. E., Maany, V., Mozley, P. D., Swanson, C. et al., Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 1998, 155, 1711-1717.
3. Lieberman, J. A., Tollefson, G. D., Charles, C., Zipursky, R. et al., Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62, 361-370.
4. Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., Magnotta, V., Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68, 128-137.
5. Mackay, A. V., Iversen, L. L., Rossor, M., Spokes, E. et al., Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 1982, 39, 991-997.
6. Kornhuber, J., Riederer, P., Reynolds, G. P., Beckmann, H. et al., 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J. Neural Transm. 1989, 75, 1-10.
7. Lahti, A. C., Weiler, M. A., Holcomb, H. H., Tamminga, C. A., Cropsey, K. L., Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 2009, 34, 2675-2690.
8. Snitz, B. E., MacDonald, A., 3rd, Cohen, J. D., Cho, R. Y. et al., Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am. J. Psychiatry 2005, 162, 2322-2329.
9. Lidow, M. S., Song, Z. M., Castner, S. A., Allen, P. B. et al., Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol. Psychiatry 2001, 49, 1-12.
10. Selemon, L. D., Lidow, M. S., Goldman-Rakic, P. S., Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol. Psychiatry 1999, 46, 161-172.
11. Konradi, C., Heckers, S., Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry 2001, 50, 729-742.
12. Altunkaynak, B. Z., Ozbek, E., Unal, B., Aydin, N. et al., Chronic treatment of haloperidol induces pathological changes in striatal neurons of guinea pigs: a light and electron microscopical study. Drug Chem. Toxicol. 2012, 35, 406-411.
13. Mamah, D., Harms, M. P., Barch, D., Styner, M. et al., Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Front. Psychiatry 2012, 3:96.
14. Pizzolato, G., Soncrant, T. T., Rapoport, S. I., Haloperidol and cerebral metabolism in the conscious rat: relation to pharmacokinetics. J. Neurochem. 1984, 43, 724-732.
15. Wotanis, J., Hanak, S. E., Wettstein, J. G., Black, M. D., Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mapping. Schizophr. Res. 2003, 61, 195-205.
16. Miller, D. D., Andreasen, N. C., O'Leary, D. S., Rezai, K. et al., Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 1997, 17, 230-240.
17. Cohen, R. M., Nordahl, T. E., Semple, W. E., Pickar, D., The brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia: evidence of a sex effect. Neuropsychopharmacology 1999, 21, 632-640.
18. Molina, V., Gispert, J. D., Reig, S., Sanz, J. et al., Cerebral metabolism and risperidone treatment in schizophrenia. Schizophr. Res. 2003, 60, 1-7.
19. Lahti, A. C., Holcomb, H. H., Weiler, M. A., Medoff, D. R. et al., Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology 2004, 29, 171-178.
20. Schmitt, A., Weber, S., Jatzko, A., Braus, D. F. et al., Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. J. Neural Transm. 2004, 111, 91-100.
21. Vernon, A. C., Natesan, S., Modo, M., Kapur, S., Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 2011, 69, 936-944.
22. Vernon, A. C., Crum, W. R., Lerch, J. P., Chege, W. et al., Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol. Psychiatry 2014, 75, 982-990.
23. Altar, C. A., in: Burger, A., Abraham, D. J. (Eds.), Burger's Medicinal Chemistry and Drug Discovery, Wiley and Sons, Hoboken 2003, pp. 599-672.
24. Altar, C. A., Vawter, M. P., Ginsberg, S. D., Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 2009, 34, 18-54.
25. Bachmann, R. F., Schloesser, R. J., Gould, T. D., Manji, H. K., Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol. Neurobiol. 2005, 32, 173-202.
26. Gould, T. D., Quiroz, J. A., Singh, J., Zarate, C. A. et al., Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry 2004, 9, 734-755.
27. Lewis, D. A., Antipsychotic medications and brain volume: do we have cause for concern? Arch. Gen. Psychiatry 2011, 68, 126-127.
28. Halim, N. D., Weickert, C. S., McClintock, B. W., Weinberger, D. R. et al., Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, 29, 1063-1069.
29. Hakansson, K., Pozzi, L., Usiello, A., Haycock, J. et al., Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur. J. Neurosci. 2004, 20, 1108-1112.
30. Lipska, B. K., Khaing, Z. Z., Weickert, C. S., Weinberger, D. R., BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci. 2001, 14, 135-144.
31. Farrelly, L. A., Dicker, P., Wynne, K., English, J. et al., Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex. Proteomics 2014, 14, 1574-1578.
32. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
33. Vale, R. D., The molecular motor toolbox for intracellular transport. Cell 2003, 112, 467-480.
34. Glantz, L. A., Lewis, D. A., Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57, 65-73.
35. Ellison-Wright, I., Bullmore, E., Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr. Res. 2010, 117, 1-12.
36. Connor, C. M., Crawford, B. C., Akbarian, S., White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosc. 2011, 29, 325-334.
37. Arnold, S. E., Lee, V. M., Gur, R. E., Trojanowski, J. Q., Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc. Natl. Acad. Sci. USA 1991, 88, 10850-10854.
38. Rioux, L., Ruscheinsky, D., Arnold, S. E., Microtubule-associated protein MAP2 expression in olfactory bulb in schizophrenia. Psychiatry Res. 2004, 128, 1-7.
39. Somenarain, L., Jones, L. B., A comparative study of MAP2 immunostaining in areas 9 and 17 in schizophrenia and Huntington chorea. J. Psychiatr. Res. 2010, 44, 694-699.
40. Solis-Chagoyan, H., Calixto, E., Figueroa, A., Montano, L. M. et al., Microtubule organization and L-type voltage-activated calcium current in olfactory neuronal cells obtained from patients with schizophrenia and bipolar disorder. Schizophr. Res. 2013, 143, 384-389.
41. Brown, J. W., Rueter, L. E., Zhang, M., Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 49, 53-62.
42. English, J. A., Dicker, P., Focking, M., Dunn, M. J., Cotter, D. R., 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009, 9, 3368-3382.
43. Benitez-King, G., Ramirez-Rodriguez, G., Ortiz, L., Meza, I., The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 515-533.
44. Corena-McLeod, M., Walss-Bass, C., Oliveros, A., Gordillo Villegas, A. et al., New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations. PloS One 2013, 8, e52147.
45. Duda, D. M., Scott, D. C., Calabrese, M. F., Zimmerman, E. S. et al., Structural regulation of cullin-RING ubiquitin ligase complexes. Curr. Opin. Struct. Biol. 2011, 21, 257-264.
46. Dubiel, D., Gierisch, M. E., Huang, X., Dubiel, W. et al., CAND1-dependent control of cullin 1-RING Ub ligases is essential for adipogenesis. Biochim. Biophys. Acta 2013, 1833, 1078-1084.
47. Modica-Napolitano, J. S., Lagace, C. J., Brennan, W. A., Aprille, J. R., Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. Res. 2003, 26, 951-959.
48. Prince, J. A., Yassin, M. S., Oreland, L., Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther. 1997, 280, 261-267.
49. Tabb, D. L., What's driving false discovery rates? J. Proteome Res. 2008, 7, 45-46.
50. Frost, D. O., Page, S. C., Carroll, C., Kolb, B., Early exposure to haloperidol or olanzapine induces long-term alterations of dendritic form. Synapse 2010, 64, 191-199.
51. van der Marel, K., Klomp, A., Meerhoff, G. F., Schipper, P. et al., Long-term oral methylphenidate treatment in adolescent and adult rats: differential effects on brain morphology and function. Neuropsychopharmacology 2014, 39, 263-273.
52. Malberg, J. E., Eisch, A. J., Nestler, E. J., Duman, R. S., Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20, 9104-9110.
53. Wakade, C. G., Mahadik, S. P., Waller, J. L., Chiu, F. C., Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69, 72-79.
54. Focking, M., Dicker, P., English, J. A., Schubert, K. O. et al., Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch. Gen. Psychiatry 2011, 68, 477-488.
55. Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A. et al., ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 2014, 32, 223-226.